Drugs / Quinapril
Quinapril
also known as
Accupril · Quinapril Hydrochloride · Accupro · C09AA06 · CI 906 · NSC-758222 · Quinapril HCl · Quinapril hydrochloride component of accuretic · +2 more
Small molecule targets ACE via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ACCUPRIL | — | 1993-10-29 | fda.gov ↗ |
| Approved | US (FDA) | ACCUPRIL | — | 1991-11-19 | fda.gov ↗ |
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00648011 | Aug 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649441 | Aug → Sep 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649649 | Dec 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649103 | Dec 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT05713396 | Jan 2017 → Jun 2022 | diabetes mellitus | AHEPA University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT01669434 | Jun 2015 → Nov 2016 | — | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT00313547 | Apr 2006 → Apr 2007 | hypertensive disorder | Montreal Heart Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00147524 | Oct 2003 → May 2005 | hypertensive disorder | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00188188 | Mar 2002 → ? | systemic lupus erythematosus | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT00269243 | Nov 1999 → May 2005 | — | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 4 | NCT03031834 | Jan 1999 → May 2001 | diabetic autonomic neuropathy | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01867047 | Jun 2013 → Jun 2016 | hypotensive disorder | Duke University | Terminated | No outcome recorded |
| — | NCT00154050 | May 2004 → Jul 2006 | peripheral arterial disease | Technical University Dresden | Completed | No outcome recorded |
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01581476 Comparator | Jan 2009 → Apr 2017 | type 1 diabetes mellitus | University of Cambridge | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded |
| Phase 4 | NCT00438113 Comparator | Dec 2009 → Sep 2016 | atrial fibrillation | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00651287 Comparator | Dec 2002 → Jun 2004 | hypertensive disorder | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00150826 Comparator | May 2000 → Dec 2004 | ischemic disease | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00795262 Comparator | Jul 2008 → Jul 2009 | diabetes mellitus, hypertensive disorder | InVasc Therapeutics, Inc. | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-08-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Generic Accupril® Tablets tevapharm.com ↗ |
| 2004-12-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Launches Quinapril Hcl Tablets; Pursuant To Agreement With Ranbaxy tevapharm.com ↗ |
| 2004-06-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Comments On Quinapril Court Ruling tevapharm.com ↗ |
| 2003-06-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval for Quinapril Hydrochloride Tablets tevapharm.com ↗ |
| 2002-02-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval for Quinapril HCl Tablets tevapharm.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quinapril | “Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗21“We will then attempt to reverse abnormalities in endothelial function and myocardial perfusion by therapy with an ACE inhibitor(Quinapril).” NCT00188188 ↗ “Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril” NCT04330300 ↗ “moexipril, perindopril, quinapril, ramipril, trandolapril” NCT00684489 ↗ “Quinapril 40mg/d” NCT02817360 ↗ “Quinapril” NCT01581476 ↗ “quinapril” NCT01669434 ↗ “Quinapril” NCT00741585 ↗ |
| Known as | Accupril | “Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗2“Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od.” NCT00438113 ↗ |
| Known as | Accupro | ChEMBL registry synonym — accepted as the source's own label CHEMBL1592 ↗ |
| Known as | C09AA06 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1592 ↗ |
| Known as | CI 906 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1592 ↗ |
| Known as | NSC-758222 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1592 ↗ |
| Known as | Quinapril HCl | “Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg” NCT00648011 ↗ |
| Known as | Quinapril Hydrochloride | “Quinapril Hydrochloride Tablets 40 mg” NCT00649649 ↗1“Quinapril Hydrochloride Tablets 40 mg” NCT00649103 ↗ |
| Known as | Quinapril hydrochloride component of accuretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1592 ↗ |
| Known as | Quinapril hydrochloride component of quinaretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1592 ↗ |
| Known as | Quinil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1592 ↗ |
| Action | Inhibit | “Quinapril is an effective and well-tolerated ACE-I” NCT00147524 ↗ |
| Modality | Small molecule | — CHEMBL1592 ↗ |
| Route | Oral | “Medication A(oral Quinapril or Placebo)” NCT00188188 ↗ |
| Target | ACE | “These effects are mediated through the binding of quinaprilat to both tissue and plasma-ACE.” NCT00147524 ↗ |